Much is known about the replication of the human immunodeficiencyvirus type 1 (HIV-1) from the time of cell attachment to therelease of mature virions (Figure 1), and drugs that interferewith many of the steps in HIV replication have been developedand tested in vitro. These drugs include inhibitors of reversetranscriptase, protease, and a regulatory protein, Tat (Table 1).Inhibitors of reverse transcriptase can prevent the spreadof infectious virus to new cells but do not interfere with thereplication of HIV genomes that are integrated into the hostgenome. Two of the . . . [Full Text of this Article]
Zidovudine
Clinical Use of Zidovudine
Side Effects of Zidovudine
Resistance to the Antiviral Action of Zidovudine
Didanosine
Clinical Use of Didanosine
Side Effects of Didanosine
Viral Resistance to Didanosine
Zalcitabine
Other Reverse Transcriptase Inhibitors
Inhibitors of Tat Protein
Protease Inhibitors
Therapies Based on CD4 and the HIV Envelope
Combination Therapy
Future Prospects
Source Information
From the Infectious Diseases Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, where reprint requests should be addressed to Dr. Hirsch.
References
This article has been cited by other articles:
Meyerson, M.
(2000). Role of Telomerase in Normal and Cancer Cells. JCO
18: 2626-2634
[Abstract][Full Text]
Kiriyama, A., Nishiura, T., Yamaji, H., Takada, K.
(1999). Metabolic Characterization of a Tripeptide Human Immunodeficiency Virus Type 1 Protease Inhibitor, KNI-272, in Rat Liver Microsomes. Antimicrob. Agents Chemother.
43: 549-556
[Abstract][Full Text]
Sham, H. L., Kempf, D. J., Molla, A., Marsh, K. C., Kumar, G. N., Chen, C.-M., Kati, W., Stewart, K., Lal, R., Hsu, A., Betebenner, D., Korneyeva, M., Vasavanonda, S., McDonald, E., Saldivar, A., Wideburg, N., Chen, X., Niu, P., Park, C., Jayanti, V., Grabowski, B., Granneman, G. R., Sun, E., Japour, A. J., Leonard, J. M., Plattner, J. J., Norbeck, D. W.
(1998). ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease. Antimicrob. Agents Chemother.
42: 3218-3224
[Abstract][Full Text]
Trapnell, C. B., Klecker, R. W., Jamis-Dow, C., Collins, J. M.
(1998). Glucuronidation of 3'-Azido-3'-Deoxythymidine (Zidovudine) by Human Liver Microsomes: Relevance to Clinical Pharmacokinetic Interactions with Atovaquone, Fluconazole, Methadone, and Valproic Acid. Antimicrob. Agents Chemother.
42: 1592-1596
[Abstract][Full Text]
Cato, A. III, Qian, J., Hsu, A., Levy, B., Leonard, J., Granneman, R.
(1998). Multidose Pharmacokinetics of Ritonavir and Zidovudine in Human Immunodeficiency Virus-Infected Patients. Antimicrob. Agents Chemother.
42: 1788-1793
[Abstract][Full Text]
Oliphant, C. M., Bonnema, S. M.
(1997). New Advances in the Pharmacological Treatment of Human Immunodeficiency Virus (HIV) Infection: Focus on Protease Inhibitors. Journal of Pharmacy Practice
10: 20-51
[Abstract]
Markowitz, M., Saag, M., Powderly, W. G., Hurley, A. M., Hsu, A., Valdes, J. M., Henry, D., Sattler, F., Marca, A. L., Leonard, J. M., Ho, D. D.
(1995). A Preliminary Study of Ritonavir, an Inhibitor of HIV-1 Protease, to Treat HIV-1 Infection. NEJM
333: 1534-1540
[Abstract][Full Text]
Koopmans, P P
(1995). Registration of drugs for treating cancer and HIV infection: a plea to carry out phase 3 trials before admission to the market. BMJ
310: 1305-1306
[Full Text]
Fauci, A.
(1993). Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science
262: 1011-1018
[Abstract]
Bartlett, J. G.
(1993). Zidovudine Now or Later?. NEJM
329: 351-352
[Full Text]
Previous
